A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer.
complement component 1q
efficacy prediction
immunotherapy
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
04
2021
accepted:
26
05
2021
entrez:
17
9
2021
pubmed:
18
9
2021
medline:
18
9
2021
Statut:
epublish
Résumé
To evaluate the value of serum complement component 1q (C1q) levels in predicting the efficacy of combined immunotherapy in patients with lung cancer. A total of 42 patients with lung cancer who received combined immunotherapy in the cancer center of Renmin Hospital of Wuhan University were included in this study. The clinical data of serum C1q and lactate dehydrogenase (LDH) levels before and three weeks after immunotherapy were collected. Response evaluation showed that the number of patients with complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) was 0 (0%), 26 (61.9%), 14 (33.3%), and 2 (4.8%), respectively. The CR/PR group (patients with CR or PR) showed higher High C1q levels before immunotherapy and increased C1q levels and decreased LDH levels 3 weeks afterward suggest good therapeutic effects of combined immunotherapy in patients with lung cancer. Serum C1q levels have certain clinical significance in predicting the efficacy of combined immunotherapy.
Identifiants
pubmed: 34531687
doi: 10.2147/CMAR.S314369
pii: 314369
pmc: PMC8439965
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7131-7137Informations de copyright
© 2021 Zhang et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest regarding the publication of this paper.
Références
Memo. 2016;9(4):201-206
pubmed: 28058063
Front Immunol. 2017 May 24;8:592
pubmed: 28596769
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
PLoS One. 2009 Jun 01;4(6):e5755
pubmed: 19484134
Front Immunol. 2017 Nov 20;8:1559
pubmed: 29209316
Cell Rep. 2014 Mar 27;6(6):1085-1095
pubmed: 24613353
Nat Commun. 2016 Feb 01;7:10346
pubmed: 26831747
PLoS One. 2018 Jul 26;13(7):e0200633
pubmed: 30048458
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
BMC Cancer. 2019 Jun 10;19(1):558
pubmed: 31182061
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Immunotherapy. 2021 May;13(7):621-631
pubmed: 33775103
Cancers (Basel). 2021 Mar 22;13(6):
pubmed: 33809974
J Clin Oncol. 2018 Jun 10;36(17):1685-1694
pubmed: 29489427
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Nat Rev Immunol. 2018 Jan;18(1):5-18
pubmed: 28920587
Cochrane Database Syst Rev. 2017 Dec 16;12:CD011300
pubmed: 29247502
J Immunol. 2012 Nov 1;189(9):4674-83
pubmed: 23028051
Immunopharmacology. 2000 Aug;49(1-2):159-70
pubmed: 10904115
J Cell Physiol. 2020 Jan;235(1):74-86
pubmed: 31222740
Anticancer Res. 2017 Oct;37(10):5857-5862
pubmed: 28982912
J Thorac Dis. 2019 Apr;11(4):1117-1123
pubmed: 31179053
Future Oncol. 2019 Jul;15(20):2423-2433
pubmed: 31237152
Expert Opin Biol Ther. 2008 Jun;8(6):759-68
pubmed: 18476787
Adv Ther. 2019 Oct;36(10):2638-2678
pubmed: 31410780
Br J Cancer. 2003 Sep 1;89(5):877-85
pubmed: 12942121
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851